Journal
FUTURE ONCOLOGY
Volume 13, Issue 24, Pages 2183-2193Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0245
Keywords
circulating tumor DNA; GIST; KIT; PDGFR alpha; quadruple WT GIST
Categories
Funding
- ArQule
- Daiichi Sankyo
- Merck Sharp Dohme
- Novartis
Ask authors/readers for more resources
Gastrointestinal stromal tumors (GISTs) are the most common GI tract mesenchymal tumors. GIST patients are optimally managed by a precision medicine approach. Herein, we discuss the latest advances in precision medicine and ongoing clinical trials relevant to GIST. Circulating tumor DNA for detection of mutational changes could replace tissue biopsies and radiographic imaging once validated. Most GISTs are KIT/PDGFR alpha mutated, and despite the good clinical response to imatinib, treatment is generally not curative, more often due to secondary mutations. New mechanisms to bypass this resistance by inhibiting KIT downstream pathways and by targeting multiple KIT or PDGFR alpha mutations are being investigated. Immunotherapy for GIST patients is in its infancy. These approaches may lead to more effective, less toxic therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available